相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
Ulf Landmesser et al.
CARDIOVASCULAR RESEARCH (2021)
Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain
Peter G. Chandler et al.
CELLS (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor
Lorenzo Da Dalt et al.
EUROPEAN HEART JOURNAL (2019)
LOW DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION AND SAFETY WITH LIB003, AN ANTI-PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 FUSION PROTEIN: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY
Evan A. Stein et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Cholesterol metabolism, pancreatic β-cell function and diabetes
Carla Perego et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2019)
SAFETY, TOLERABILITY AND LDL-C REDUCTION WITH A NOVEL ANTI-PCSK9 RECOMBINANT FUSION PROTEIN (LIB003): RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY
E. Stein et al.
ATHEROSCLEROSIS (2019)
INCLISIRAN DURABLY LOWERS LDL-C AND PCSK9 EXPRESSION IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA: THE ORION-2 PILOT STUDY
F. Raal et al.
ATHEROSCLEROSIS (2019)
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Kausik K. Ray et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial
Kausik K. Ray et al.
JAMA CARDIOLOGY (2019)
Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies
Nabil G. Seidah et al.
CARDIOVASCULAR RESEARCH (2019)
被撤回的出版物: Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis (Retracted article. See vol. 21, 2023)
Amir Abbas Momtazi-Borojeni et al.
BMC MEDICINE (2019)
Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake
Adri M. Galvan et al.
JOURNAL OF LIPID RESEARCH (2019)
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER
Marc S. Sabatine et al.
CIRCULATION (2018)
Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins Prespecified Secondary End Points in ORION 1
Kausik K. Ray et al.
CIRCULATION (2018)
Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis
Ye-Xuan Cao et al.
DIABETES OBESITY & METABOLISM (2018)
Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
Andrea Baragetti et al.
PHARMACOLOGICAL RESEARCH (2018)
Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice
Ryo Kawakami et al.
PLOS ONE (2018)
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
Michel Farnier et al.
ATHEROSCLEROSIS (2018)
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Marc P. Bonaca et al.
CIRCULATION (2018)
RNA Therapeutics in Cardiovascular Precision Medicine
Ageliki Laina et al.
FRONTIERS IN PHYSIOLOGY (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
Christine Landlinger et al.
EUROPEAN HEART JOURNAL (2017)
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab Pooled Data From Randomized Trials
Jennifer G. Robinson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Robert P. Giugliano et al.
LANCET (2017)
Cognitive Function in a Randomized Trial of Evolocumab
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antidrug Antibodies in Patients Treated with Alirocumab
Eli M. Roth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
Camilla Gustafsen et al.
NATURE COMMUNICATIONS (2017)
PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
Andrea Baragetti et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2017)
Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain
Nathanael G. Lintner et al.
PLOS BIOLOGY (2017)
Genetic Architecture of Familial Hypercholesterolaemia
Mahtab Sharifi et al.
CURRENT CARDIOLOGY REPORTS (2017)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Marc S. Sabatine et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
Amand F. Schmidt et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol A Prespecified Analysis of the IMPROVE-IT Trial
Robert P. Giugliano et al.
JAMA CARDIOLOGY (2017)
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia Results Up to 4 Years From the Open-Label OSLER-1 Extension Study
Michael J. Koren et al.
JAMA CARDIOLOGY (2017)
A Therapeutic Peptide Vaccine Against PCSK9
Yajie Pan et al.
SCIENTIFIC REPORTS (2017)
Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies
Peter P. Toth et al.
CIRCULATION (2017)
Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
Peter H. Jones et al.
AMERICAN JOURNAL OF CARDIOLOGY (2016)
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
Giuseppe Danilo Norata et al.
CARDIOVASCULAR RESEARCH (2016)
Asialoglycoprotein receptor 1 is a specific cell-surface marker for isolating hepatocytes derived from human pluripotent stem cells
Derek T. Peters et al.
DEVELOPMENT (2016)
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes A Meta-analysis
Luca A. Lotta et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Brian A. Ference et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese
Clara S. Tang et al.
NATURE COMMUNICATIONS (2015)
Antisense Oligonucleotide Therapies: The Promise and the Challenges from a Toxicologic Pathologist's Perspective
Kendall S. Frazier
TOXICOLOGIC PATHOLOGY (2015)
Variable effects of gender and Western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL/6 mice
Majambu Mbikay et al.
JOURNAL OF DIABETES (2015)
Targeting PCSK9 for Hypercholesterolemia
Giuseppe Danilo Norata et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54 (2014)
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
Thomas A. Lagace
CURRENT OPINION IN LIPIDOLOGY (2014)
LDL CHOLESTEROL REDUCTION WITH BMS-962476, AN ADNECTIN INHIBITOR OF PCSK9: RESULTS OF A SINGLE ASCENDING DOSE STUDY
Evan A. Stein et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
Giuseppe Danilo Norata et al.
VASCULAR PHARMACOLOGY (2014)
Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering
Tracy Mitchell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Giuseppe Danilo Norata et al.
EUROPEAN HEART JOURNAL (2013)
Gene silencing approaches for the management of dyslipidaemia
Giuseppe Danilo Norata et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
Silencing disease genes in the laboratory and the clinic
Jonathan K. Watts et al.
JOURNAL OF PATHOLOGY (2012)
Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
G. Tibolla et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2011)
Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles
Giuseppe Danilo Norata et al.
ATHEROSCLEROSIS (2010)
Genetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population
Yasuko Miyake et al.
ATHEROSCLEROSIS (2008)
A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction
Sekar Kathiresan
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
分享论文
